Received tentative approval from the FDA for YUTREPIATM (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) ...

Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are ...

The company is effectively advancing its research, particularly with the anticipated Phase 3 PROSERA data expected in the fourth quarter of 2025 and the initiation of a Phase 3 trial for pulmonary ...

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...

a caspase inhibitor for injection in the treatment of acute/acute on-chronic liver failure. Preclinical Development Updates F230: F230 is a selective endothelin receptor agonist for the treatment of ...

One such firm is working to treat cystic fibrosis - an inherited, life-threatening condition that can cause severe damage to ...

Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

Finally, as shared earlier today, KOMET has potential to extend Koselugo use beyond pediatric NF1-PN patients to adults and WAYPOINT has the potential to bring a first-in-class mechanism of action to ...